Allogenetics provides aunique solution to the problem of organ rejection following transplantation.
Allogenetics has raised $3.8M in total funding. The most recent round was Seed. The last funding was announced in August 2024.
Allogenetics's investors include Carma Fund, NBank Capital.
Allogenetics is headquartered in Hanover, Germany.
Allogenetics provides aunique solution to the problem of organ rejection following transplantation.
Allogenetics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Allogenetics — Funding & Investors." VCBacked, August 29, 2024, https://www.vcbacked.co/company/allogenetics. Accessed September 15, 2026.
VCBacked. (2024). Allogenetics — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/allogenetics
{{cite web |title=Allogenetics — Funding & Investors |url=https://www.vcbacked.co/company/allogenetics |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated